
Biotech Surges Following Positive Phase 2A Observations
Traders were quick to snatch up shares of %Immuneering Corporation (Nasdaq: $IMRX) after the announcement, with shares of the micro cap currently bid up 68.18 percent at the time of writing. This bullish performance will be a strong continuation of Thursday’s trading after shares closed up at $1.43/share (+10.85%). Keep an eye on this one!
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment